Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma | Zendy

Michael A. Postow | Zendy; Jason Chesney | Zendy; Anna C. Pavlick | Zendy; Caroline Robert | Zendy; Kenneth F. Grossmann | Zendy; David F. McDermott | Zendy; Gerald P. Linette | Zendy; Nicolás Meyer | Zendy; Jeffrey K. Giguere | Zendy; Sanjiv S. Agarwala | Zendy; Montaser Shaheen | Zendy; Marc S. Ernstoff | Zendy; David R. Minor | Zendy; April K.S. Salama | Zendy; Matthew H. Taylor | Zendy; Patrick A. Ott | Zendy; Linda M. Rollin | Zendy; Christine E. Horak | Zendy; Paul Gagnier | Zendy; Jedd D. Wolchok | Zendy; F. Stephen Hodi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Author(s) -

Michael A. Postow,

Jason Chesney,

Anna C. Pavlick,

Caroline Robert,

Kenneth F. Grossmann,

David F. McDermott,

Gerald P. Linette,

Nicolás Meyer,

Jeffrey K. Giguere,

Sanjiv S. Agarwala,

Montaser Shaheen,

Marc S. Ernstoff,

David R. Minor,

April K.S. Salama,

Matthew H. Taylor,

Patrick A. Ott,

Linda M. Rollin,

Christine E. Horak,

Paul Gagnier,

Jedd D. Wolchok,

F. Stephen Hodi

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1414428

Subject(s) - ipilimumab , nivolumab , medicine , melanoma , hazard ratio , placebo , combination therapy , clinical endpoint , oncology , gastroenterology , confidence interval , surgery , clinical trial , cancer , immunotherapy , pathology , cancer research , alternative medicine

In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research